We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent (A) Boosts LSAG Segment With Advanced Dilution System
Read MoreHide Full Article
Agilent Technologies (A - Free Report) recently introduced the Advanced Dilution System (ADS) 2 to address the problems on auto-dilution adoption.
The ADS 2 enhances workflow efficiency within the laboratory by integrating with Agilent auto-samplers, ICP-OES and ICP-MS instruments and software.
Further, the solution offers a robust, efficient and user-friendly production environment, utilizing unique flow path technology for diluted and undiluted sample analysis, and consistent data handling and reporting.
Agilent is expected to gain solid traction across routine food, environmental, pharmaceutical testing and battery research laboratories on the back of its latest move.
Moreover, the new launch will enable the company to capitalize on growth opportunities present in the global analytical instrumentation market. Per a Mordor Intelligence report, the analytical instrumentation market is expected to reach $66.3 billion by 2028, witnessing a CAGR of 6% between 2023 and 2028.
LSAG Segment in Focus
The latest move is in sync with the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment.
Notably, the company showcased its expanded InfinityLab GPC/SEC Solution at the HPLC Conference 2023 in Düsseldorf. The solution includes a dedicated column thermostat, multi-angle light scattering detector, GPC/SEC-Ready Kit, and WinGPC Software for advanced material characterization.
Additionally, Agilent's 1260 Infinity II Hybrid Multisampler, 1290 Infinity II Bio Online Sample Manager and Revident Quadrupole Time-of-Flight liquid chromatography-mass spectrometry (LC/MS) system were also displayed at the HPLC 2023 conference.
The company also signed a Memorandum of Understanding with the Sarawak Infectious Disease Centre to provide its 6475 triple quadrupole LC/MS system for neglected tropical diseases research, further strengthening the LSAG segment on the back of a growing clientele.
Wrapping Up
A strengthening LSAG segment is expected to aid the company’s overall financial performance in the near term.
However, the underlined segment is suffering due to sluggish capital equipment spending by customers.
Moreover, macroeconomic uncertainties and softening demand in China remain concerning for the company. Agilent’s shares have gained 4.7% in the year-to-date period, underperforming the Zacks Computer & Technology sector’s 12.2% growth.
The Zacks Consensus Estimate for second-quarter fiscal 2024 total revenues is $1.58 billion, indicating a year-over-year decline of 7.8%.
The consensus mark for second-quarter fiscal 2024 earnings is pegged at $1.19 per share, exhibiting a year-over-year decline of 6.3%.
Zacks Rank & Stocks to Consider
Currently, Agilent carries a Zacks Rank #3 (Hold).
Image: Bigstock
Agilent (A) Boosts LSAG Segment With Advanced Dilution System
Agilent Technologies (A - Free Report) recently introduced the Advanced Dilution System (ADS) 2 to address the problems on auto-dilution adoption.
The ADS 2 enhances workflow efficiency within the laboratory by integrating with Agilent auto-samplers, ICP-OES and ICP-MS instruments and software.
Further, the solution offers a robust, efficient and user-friendly production environment, utilizing unique flow path technology for diluted and undiluted sample analysis, and consistent data handling and reporting.
Agilent is expected to gain solid traction across routine food, environmental, pharmaceutical testing and battery research laboratories on the back of its latest move.
Moreover, the new launch will enable the company to capitalize on growth opportunities present in the global analytical instrumentation market. Per a Mordor Intelligence report, the analytical instrumentation market is expected to reach $66.3 billion by 2028, witnessing a CAGR of 6% between 2023 and 2028.
LSAG Segment in Focus
The latest move is in sync with the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment.
Notably, the company showcased its expanded InfinityLab GPC/SEC Solution at the HPLC Conference 2023 in Düsseldorf. The solution includes a dedicated column thermostat, multi-angle light scattering detector, GPC/SEC-Ready Kit, and WinGPC Software for advanced material characterization.
Additionally, Agilent's 1260 Infinity II Hybrid Multisampler, 1290 Infinity II Bio Online Sample Manager and Revident Quadrupole Time-of-Flight liquid chromatography-mass spectrometry (LC/MS) system were also displayed at the HPLC 2023 conference.
The company also signed a Memorandum of Understanding with the Sarawak Infectious Disease Centre to provide its 6475 triple quadrupole LC/MS system for neglected tropical diseases research, further strengthening the LSAG segment on the back of a growing clientele.
Wrapping Up
A strengthening LSAG segment is expected to aid the company’s overall financial performance in the near term.
However, the underlined segment is suffering due to sluggish capital equipment spending by customers.
Moreover, macroeconomic uncertainties and softening demand in China remain concerning for the company. Agilent’s shares have gained 4.7% in the year-to-date period, underperforming the Zacks Computer & Technology sector’s 12.2% growth.
The Zacks Consensus Estimate for second-quarter fiscal 2024 total revenues is $1.58 billion, indicating a year-over-year decline of 7.8%.
The consensus mark for second-quarter fiscal 2024 earnings is pegged at $1.19 per share, exhibiting a year-over-year decline of 6.3%.
Zacks Rank & Stocks to Consider
Currently, Agilent carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader technology sector are Applied Materials (AMAT - Free Report) , BlackLine (BL - Free Report) and AMETEK (AME - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of Applied Materials have gained 28.8% in the year-to-date period. The long-term earnings growth rate for ABNB is 16.85%.
Shares of BlackLine have risen 2.5% in the year-to-date period. The long-term earnings growth rate for BL is currently projected at 5.50%.
Shares of AMETEK have gained 9.4% in the year-to-date period. The long-term earnings growth rate for AME is 9.19%.